期刊文献+

司帕沙星在实验性感染大肠杆菌-败血霉形体病鸡体内的组织动力学及残留研究

Tissues pharmacokinetics and residues of sparfloxacin in experimentally induced E.coli-Mycoplasma gallisepticu disease chickens
在线阅读 下载PDF
导出
摘要 实验性感染大肠杆菌—败血霉形体病鸡,单剂量(5 mg.kg-1)内服司帕沙星,研究其组织动力学和残留情况。采用HPLC面积-内标法测定各组织中司帕沙星浓度,利用药动学分析软件MCPKP分析药-时数据。疾病模型鸡肝脏、肺脏和心脏中的药—时数据符合一级吸收三项指数方程,主要动力学参数为:t1/2α0.3505,0.8381,0.6005 h;t1/2β11.7802,13.8479,2.4578 h;tmax 1.0653,1.1397,0.7546 h;Cmax 3.3591,2.2951,1.7226μg.mL-1;AUC24.4230,30.663,5.3780 mg.L-1.h-1,Tcp(ther)81.0240,108.52,18.410 h。肾脏和肌肉组织中药-时数据符合一级吸收二项指数方程,主要动力学参数为:t1/2K 2.2287,7.5072 h;tmax1.4655,1.8644 h;Cmax1.9926,1.1317μg.mL-1;AUC9.8536,14.5240 mg.L-1.h-1;Tcp(ther)19.923,58.156 h。各组织中药物浓度降至0.001 mg.kg-1时需休药7 d。 A single dose (5 mg· kg^-1) of sparfloxacin was oral administered to experimentally induced E.coliMG chickens. The drug concentrations in tissues were detected by HPLC and the pharmacokinetics parameters were analyzed with MCPKP. The results showed that the liver, lung and heart concentration-time curves after oral administration were best described by a tri-exponential equation with the first order absorption. The main pharmacokinetic parameters were as follows: t1/2α0.3505,0.8381,0.6005 h;t1/2β11.7802,13.8479,2.4578 h;tmax1.0653,1.1397,0.7546 h;Cmax3.3591,2.295 1,1.7226μg·mL-1;AUC 24.4230,30.663,5.3780 ng·L-1·h-1,Tcp(ther)81.0240,108.52,18.410 h respectively. The kidney and muscle concentration-time data fitted the bi-exponential equation with first order absorption. Their main pharmacokinetic parameters were: t1/2k 2.2287,7.5072 h;tmax 1.4655,1.8644 h;Cmax1.9926,1.1317μg·mL-1;AUC 9.8536,14.5240mg·L-1·h-1;Tcp(ther)19.923,58.156h respectively. The withdrawal time of sparfloxacin concentrations in tissues reduce to 0.001 μg ·mL^-1 were suggested as 7 days.
出处 《东北农业大学学报》 CAS CSCD 2006年第5期646-649,共4页 Journal of Northeast Agricultural University
基金 辽宁省博士启动基金(1040175) 辽宁省教育厅科学研究计(划202053102)项目
关键词 司帕沙星 大肠杆菌-败血霉形体感染鸡 组织动力学 残留 sparfloxacin Escherichia coli.-Mycoplasma gallisepticu disease chickens pharmacokinetics residues
  • 相关文献

参考文献4

  • 1Hoogkamp Korstanje J A.In vitro activities of ciprofloxacin,levofloxacin,lomefloxacin,ofloxacin,pefloxacin,sparfloxacin and trovaflocacin against gram-positive and gram-negative pathogens from respiratory trac infections[J].J Antimicrob Chemother,1997,40(3):427.
  • 2Ellie Hershberger,Elizabeth A C,Glenn W K,et al.Comparison of a rabbit model of bacterial endocarditis and an In vitro Infection model with simulated endocardial vegetations[J].Antimicrobial Agents and Chemotherapy,2000,44(7):1921-1924.
  • 3刘明春,佟恒敏,朱文波,孙相志,何剑斌,赵玉军.司帕沙星在雏鸡体内药代动力学及残留的研究[J].现代畜牧兽医,2004(11):37-39. 被引量:4
  • 4夏文江 成章瑞.MCPKP-药物动力学室分析的一种微机程序[J].中国药理学报,1988,9:188-188.

二级参考文献4

  • 1许铁男.新喹诺酮类抗菌药司帕沙星的药代动力学[J].国外医药(抗生素分册),1996,17(3):220-223. 被引量:13
  • 2Hakamura S, Minami A, Nakata K, et al. In vitro and in vivo antibacterial activities of AT-4140, a new broadspectrum quinolone [J]. Antimicrob Agents Chemother, 1989,33(8): 1167.
  • 3Hoogkamp Korstanje JA. In vitro activities of ciprofloxacin,levofloxacin, lomefloxacin, ofloxacin, pefioxacin, sparfloxacin and trovaflocacin against gram-positive and gram-negative pathogens from respiratory trac infections[J]. J Antimicrob Chemother, 1997,40(3) :427.
  • 4刘明春,佟恒敏,马兴元,赵玉军.司帕沙星体外抗菌活性的试验[J].中国兽医科技,2003,33(5):52-54. 被引量:2

共引文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部